v3.26.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows from Operating Activities:    
Net Loss $ (4,336,355) $ (3,781,832)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on change in fair value of convertible notes (550,380)
Interest expense paid through sale of common stock 131,479
Amortization of prepaid contracts 380,183 380,182
Stock-based compensation 991,989 883,942
Shares issued for services 66,000
Change in operating lease right of use asset and lease liabilities 2,710 (1,908)
Decreases (increases) in operating assets and liabilities:    
Accounts receivable (7,604)
Prepaid contracts (60,132)
PharmAla escrow deposit -other assets (600,000)
Inventory 24,500
Other assets (22,467)
Accounts payable and accrued expenses 279,597 177,481
Accrued compensation 16,680 442,826
Deferred revenue 124  
Refund liability 2,351  
Accrued interest (39,829) 2,178
Net cash used in operating activities (3,727,022) (1,891,263)
Cash Flows from Financing Activities:    
Proceeds from exercise of stock options 5,507
Payment on convertible note payable (405,953)
Proceeds from offering, net of costs 1,860,000
Net cash provided by financing activities 1,459,554
Net Change in Cash (2,267,468) (1,891,263)
Beginning of period 3,789,342 3,769,510
End of period 1,521,874 1,878,247
Supplemental disclosure of cash flow information:    
Cash paid for interest 87,154 186
Operating lease right-of-use asset obtained in exchange for operating lease liability 222,796
Schedule of Non-Cash Investing and Financing Activities:    
Payment of convertible note from issuance of common stock 2,813,265
Stock issued in connection with interest payment $ 125,426